Literature DB >> 27010563

Possible role for anisodamine in organophosphate poisoning.

Arik Eisenkraft1,2,3, Avshalom Falk1.   

Abstract

In cases of organophosphate poisoning, patients are treated with a combination of antidotes. In addition to these poison-directed antidotes, patients may require extra oxygen and artificial ventilation; other modalities may also be needed due to the wide range of toxic effects. Anisodamine is a belladonna alkaloid, and like other drugs from this family is non subtype-selective muscarinic, and a nicotinic cholinoceptor antagonist, which has been employed in traditional Chinese medicine. As a muscarinic antagonist, it displays similar pharmacological effects to atropine and scopolamine. However, anisodamine is not only less potent than atropine and scopolamine but also less toxic. Current in vitro and animal model studies have demonstrated that anisodamine has protective effects in a variety of diseases. Organophosphate poisoning involves not only the central and peripheral nervous systems, but also the cardiac and respiratory systems, as well as activation of inflammatory processes and oxidative stress. Therefore, the anticholinergic and additional activities of anisodamine appear to be relevant and justify its consideration as an addition to the existing remedies. However, more research is needed, as at present data on the role of anisodamine in the management of organophosphate poisoning are limited. Here, we review the beneficial effects of anisodamine on processes relevant to organophosphate poisoning.
© 2016 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27010563      PMCID: PMC4867748          DOI: 10.1111/bph.13486

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  108 in total

1.  New drugs derived from medicinal plants.

Authors:  J T Zhang
Journal:  Therapie       Date:  2002 Mar-Apr       Impact factor: 2.070

Review 2.  Cholinergic control of inflammation.

Authors:  M Rosas-Ballina; K J Tracey
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

3.  Lessons learned from the Syrian sarin attack: evaluation of a clinical syndrome through social media.

Authors:  Yossi Rosman; Arik Eisenkraft; Nadav Milk; Arthur Shiyovich; Nimrod Ophir; Shai Shrot; Yitshak Kreiss; Michael Kassirer
Journal:  Ann Intern Med       Date:  2014-05-06       Impact factor: 25.391

4.  Butyrylcholinesterase in guinea pig lung lavage: a novel biomarker to assess lung injury following inhalation exposure to nerve agent VX.

Authors:  Jacob R Graham; Benjamin S Wright; Peter E Rezk; Richard K Gordon; Alfred M Sciuto; Madhusoodana P Nambiar
Journal:  Inhal Toxicol       Date:  2006-06       Impact factor: 2.724

5.  Anisodamine antagonizes acetylcholine-induced inhibition of adrenergic neurotransmission in the canine saphenous vein.

Authors:  H Guo; R R Lorenz; P M Vanhoutte
Journal:  Chin Med Sci J       Date:  1992-03

Review 6.  Guidelines for treating cardiac manifestations of organophosphates poisoning with special emphasis on long QT and Torsades De Pointes.

Authors:  Eran Bar-Meir; Ophir Schein; Arik Eisenkraft; Ronen Rubinshtein; Ahuva Grubstein; Arie Militianu; Michael Glikson
Journal:  Crit Rev Toxicol       Date:  2007-03       Impact factor: 5.635

7.  Signal pathway involved in inhibition by lipoxin A(4) of production of interleukins induced in endothelial cells by lipopolysaccharide.

Authors:  Sheng-Hua Wu; P-Y Liao; L Dong; Z-Q Chen
Journal:  Inflamm Res       Date:  2008-09       Impact factor: 4.575

8.  Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial.

Authors:  G U Meduri; A S Headley; E Golden; S J Carson; R A Umberger; T Kelso; E A Tolley
Journal:  JAMA       Date:  1998-07-08       Impact factor: 56.272

9.  Speed of initial atropinisation in significant organophosphorus pesticide poisoning--a systematic comparison of recommended regimens.

Authors:  Michael Eddleston; Nick A Buckley; Helaina Checketts; Lalith Senarathna; Fahim Mohamed; M H Rezvi Sheriff; Andrew Dawson
Journal:  J Toxicol Clin Toxicol       Date:  2004

10.  Effects of combined anisodamine and neostigmine treatment on the inflammatory response and liver regeneration of obstructive jaundice rats after hepatectomy.

Authors:  Chong-Hui Li; Xuan Zhang; Xin-Lan Ge; Xin Huang; Ai-Qun Zhang; Wan-Qing Gu
Journal:  Biomed Res Int       Date:  2014-11-12       Impact factor: 3.411

View more
  6 in total

Review 1.  Possible role for anisodamine in organophosphate poisoning.

Authors:  Arik Eisenkraft; Avshalom Falk
Journal:  Br J Pharmacol       Date:  2016-04-22       Impact factor: 8.739

2.  Network Pharmacology Integrated Molecular Docking Reveals the Mechanism of Anisodamine Hydrobromide Injection against Novel Coronavirus Pneumonia.

Authors:  Jinsong Su; Zixuan Liu; Chuan Liu; Xuanhao Li; Yi Wang; Jing Zhao; Qingjiang Wu; Shichao Zheng; Yi Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2020-08-05       Impact factor: 2.629

3.  Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease.

Authors:  Wei Wei; Ni Kong; Meng-Zhen Liu; Ting Han; Jun-Feng Xu; Chong Liu
Journal:  Biochem Biophys Res Commun       Date:  2022-05-13       Impact factor: 3.322

Review 4.  Neurotoxicity in acute and repeated organophosphate exposure.

Authors:  Sean X Naughton; Alvin V Terry
Journal:  Toxicology       Date:  2018-08-23       Impact factor: 4.221

5.  Isolation, expression and biochemical characterization of recombinant hyoscyamine-6β-hydroxylase from Brugmansia sanguinea - tuning the scopolamine production.

Authors:  Conrad Fischer; Moonhyuk Kwon; Dae-Kun Ro; Marco J van Belkum; John C Vederas
Journal:  Medchemcomm       Date:  2018-05-02       Impact factor: 3.597

Review 6.  Emerging medical therapies in crush syndrome - progress report from basic sciences and potential future avenues.

Authors:  Ning Li; Xinyue Wang; Pengtao Wang; Haojun Fan; Shike Hou; Yanhua Gong
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.